Zevra Therapeutics, Inc. (ZVRA)
ZVRA Stock Price Chart
Explore Zevra Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze ZVRA price movements and trends.
ZVRA Company Profile
Discover essential business fundamentals and corporate details for Zevra Therapeutics, Inc. (ZVRA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
16 Apr 2015
Employees
59.00
Website
https://zevra.comCEO
Neil F. McFarlane
Description
Zevra Therapeutics, Inc., founded in 2006 and based in Celebration, Florida, is a biopharmaceutical company dedicated to discovering and developing innovative treatments for rare diseases. The company employs its proprietary Ligand Activated Therapy (LAT) technology to create novel prodrug versions of existing FDA-approved medications or to enable new applications for other compounds, primarily addressing serious medical conditions within the United States. Zevra's development pipeline is strategically concentrated on high-unmet-need therapeutic areas, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and various rare central nervous system (CNS) conditions, such as idiopathic hypersomnia (IH). Their lead product candidate, KP1077, which is a prodrug of d-methylphenidate (known as serdexmethylphenidate), is currently in Phase II clinical trials for the treatment of both IH and narcolepsy. Another key prodrug candidate, KP879, is also advancing through Phase II studies for stimulant use disorder. In addition to its pipeline, Zevra has successfully secured FDA approval for two products: AZSTARYS, a once-daily treatment for ADHD in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone (a prodrug of hydrocodone) and acetaminophen. The company's product portfolio also includes arimoclomol, and it holds collaboration and licensing agreements with KVK-Tech, Inc. and Commave Therapeutics SA. Formerly known as KemPharm, Inc., the company officially rebranded to Zevra Therapeutics, Inc. in February 2023.
ZVRA Financial Timeline
Browse a chronological timeline of Zevra Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is $0.08, while revenue estimate is $33.88m.
Earnings released on 6 May 2026
EPS came in at $0.60 surpassing the estimated $0.06 by +900.00%, while revenue for the quarter reached $36.22m , beating expectations by +13.33%.
Earnings released on 9 Mar 2026
EPS came in at $1.16 surpassing the estimated $0.05 by +2.20k%, while revenue for the quarter reached $34.10m , beating expectations by +21.56%.
Earnings released on 5 Nov 2025
EPS came in at -$0.01 surpassing the estimated -$0.02 by +50.00%, while revenue for the quarter reached $26.06m , missing expectations by -2.17%.
Earnings released on 12 Aug 2025
EPS came in at $1.21 falling short of the estimated $2.19 by -44.75%, while revenue for the quarter reached $25.88m , beating expectations by +5.56%.
Earnings released on 13 May 2025
EPS came in at -$0.06 surpassing the estimated -$0.21 by +71.43%, while revenue for the quarter reached $20.40m , missing expectations by -3.19%.
Earnings released on 11 Mar 2025
EPS came in at -$0.67 falling short of the estimated -$0.39 by -71.79%, while revenue for the quarter reached $12.04m , missing expectations by -27.73%.
Earnings released on 12 Nov 2024
EPS came in at -$0.69 falling short of the estimated -$0.44 by -56.82%, while revenue for the quarter reached $3.70m , missing expectations by -57.90%.
Earnings released on 13 Aug 2024
EPS came in at -$0.48 falling short of the estimated -$0.47 by -2.13%, while revenue for the quarter reached $4.45m , beating expectations by +2.04%.
Earnings released on 8 May 2024
EPS came in at -$0.40 surpassing the estimated -$0.49 by +18.37%, while revenue for the quarter reached $3.43m , missing expectations by -26.34%.
Earnings released on 28 Mar 2024
EPS came in at -$0.40 falling short of the estimated -$0.20 by -100.00%, while revenue for the quarter reached $13.22m , beating expectations by +12.58%.
Earnings released on 7 Nov 2023
EPS came in at -$0.40 falling short of the estimated -$0.29 by -37.93%, while revenue for the quarter reached $2.90m , missing expectations by -73.56%.
Earnings released on 14 Aug 2023
EPS came in at -$0.15 surpassing the estimated -$0.39 by +61.54%, while revenue for the quarter reached $8.47m , beating expectations by +179.54%.
Earnings released on 15 May 2023
EPS came in at -$0.34 falling short of the estimated -$0.26 by -30.77%, while revenue for the quarter reached $2.88m , beating expectations by +8.64%.
Earnings released on 7 Mar 2023
EPS came in at -$0.26 falling short of the estimated -$0.21 by -23.81%, while revenue for the quarter reached $2.32m , missing expectations by -25.34%.
Earnings released on 9 Nov 2022
EPS came in at -$0.19 falling short of the estimated -$0.13 by -46.15%, while revenue for the quarter reached $2.87m , missing expectations by -4.59%.
Earnings released on 11 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.12 by -58.33%, while revenue for the quarter reached $1.30m , missing expectations by -25.61%.
Earnings released on 12 May 2022
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $3.97m , beating expectations by +29.36%.
Earnings released on 30 Mar 2022
EPS came in at -$0.08 falling short of the estimated -$0.07 by -14.29%, while revenue for the quarter reached $2.58m , beating expectations by +15.53%.
Earnings released on 10 Nov 2021
EPS came in at -$0.05 surpassing the estimated -$0.07 by +28.57%, while revenue for the quarter reached $1.97m .
Earnings released on 12 Aug 2021
EPS came in at $0.21 falling short of the estimated $0.23 by -8.70%, while revenue for the quarter reached $11.99m .
ZVRA Stock Performance
Access detailed ZVRA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
